Rhythm Pharmaceuticals (RYTM) announced the presentation of new, real-world data that showed four pediatric patients with acquired hypothalamic obesity or congenital hypothalamic obesity achieved ...
-- Four Pediatric patients treated in French early-access program achieved meaningful weight reduction at three months on setmelanotide therapy -- -- Rhythm announced plans for a new substudy to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback